Recombinant Human FGF-19 Protein | R&D Systems 969-FG product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

R&D Systems

product type :

protein

product name :

Recombinant Human FGF-19 Protein

catalog :

969-FG

quantity :

25 ug

price :

259 USD

citations: 18

Reference
Huang F, Zheng X, Ma X, Jiang R, Zhou W, Zhou S, et al. Theabrownin from Pu-erh tea attenuates hypercholesterolemia via modulation of gut microbiota and bile acid metabolism. Nat Commun. 2019;10:4971 pubmed publisher
Wu X, Chien H, van Wolferen M, Kruitwagen H, Oosterhoff L, Penning L. Reduced FXR Target Gene Expression in Copper-Laden Livers of COMMD1-Deficient Dogs. Vet Sci. 2019;6: pubmed publisher
Bartz R, Fukuchi K, Ohtsuka T, Lange T, Grüner K, Watanabe I, et al. Preclinical Development of U3-1784, a Novel FGFR4 Antibody Against Cancer, and Avoidance of Its On-target Toxicity. Mol Cancer Ther. 2019;18:1832-1843 pubmed publisher
Garnier D, Li R, Delbos F, Fourrier A, Collet C, Guguen Guillouzo C, et al. Expansion of human primary hepatocytes in vitro through their amplification as liver progenitors in a 3D organoid system. Sci Rep. 2018;8:8222 pubmed publisher
Chen Y, Tsai C, Wei Y, Wu Y, Hsu W, Lin H, et al. ATOH1/RFX1/RFX3 transcription factors facilitate the differentiation and characterisation of inner ear hair cell-like cells from patient-specific induced pluripotent stem cells harbouring A8344G mutation of mitochondrial DNA. Cell Death Dis. 2018;9:437 pubmed publisher
Saito Y, Nakaoka T, Muramatsu T, Ojima H, Sukeda A, Sugiyama Y, et al. Induction of differentiation of intrahepatic cholangiocarcinoma cells to functional hepatocytes using an organoid culture system. Sci Rep. 2018;8:2821 pubmed publisher
Kim J, Jiwani T, Erwood S, Loree J, Rosenblum N. Suppressor of fused controls cerebellar neuronal differentiation in a manner modulated by GLI3 repressor and Fgf15. Dev Dyn. 2018;247:156-169 pubmed publisher
Hanker A, Garrett J, Estrada M, Moore P, Ericsson P, Koch J, et al. HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clin Cancer Res. 2017;23:4323-4334 pubmed publisher
Massafra V, Milona A, Vos H, Burgering B, van Mil S. Quantitative liver proteomics identifies FGF19 targets that couple metabolism and proliferation. PLoS ONE. 2017;12:e0171185 pubmed publisher
Ronaghi M, Nasr M, Ealy M, Durruthy Durruthy R, Waldhaus J, Diaz G, et al. Inner ear hair cell-like cells from human embryonic stem cells. Stem Cells Dev. 2014;23:1275-84 pubmed publisher
Feng S, Dakhova O, Creighton C, Ittmann M. Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression. Cancer Res. 2013;73:2551-62 pubmed publisher
Cyphert H, Ge X, Kohan A, Salati L, Zhang Y, Hillgartner F. Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21. J Biol Chem. 2012;287:25123-38 pubmed publisher
Di Maggio N, Mehrkens A, Papadimitropoulos A, Schaeren S, Heberer M, Banfi A, et al. Fibroblast growth factor-2 maintains a niche-dependent population of self-renewing highly potent non-adherent mesenchymal progenitors through FGFR2c. Stem Cells. 2012;30:1455-64 pubmed publisher
Tomlinson D, Knowles M. Altered splicing of FGFR1 is associated with high tumor grade and stage and leads to increased sensitivity to FGF1 in bladder cancer. Am J Pathol. 2010;177:2379-86 pubmed publisher
Schreuder T, Marsman H, Lenicek M, van Werven J, Nederveen A, Jansen P, et al. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol. 2010;298:G440-5 pubmed publisher
Shin D, Osborne T. FGF15/FGFR4 integrates growth factor signaling with hepatic bile acid metabolism and insulin action. J Biol Chem. 2009;284:11110-20 pubmed publisher
Schaap F, van der Gaag N, Gouma D, Jansen P. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology. 2009;49:1228-35 pubmed publisher
Nakayama T, Mutsuga N, Tosato G. FGF2 posttranscriptionally down-regulates expression of SDF1 in bone marrow stromal cells through FGFR1 IIIc. Blood. 2007;109:1363-72 pubmed

product information

brand :

R&D Systems

master code :

969-FG

SKU :

969-FG-025

product name :

Recombinant Human FGF-19 Protein

description :

The Recombinant Human FGF-19 Protein from R&D Systems is derived from E. coli. The Recombinant Human FGF-19 Protein has been validated for the following applications: Binding Activity.

target :

FGF-19

category :

Proteins and Enzymes

unit size :

25 ug

buffer :

Lyophilized from a 0.2 µm filtered solution in PBS with BSA as a carrier protein.

conjugate :

Unconjugated

purity :

>97%, by SDS-PAGE under reducing conditions and visualized by silver stain.

species :

Human

theoretical molecular weight :

21 kDa

gene symbol :

FGF19

details of functionality :

Measured by its binding ability in a functional ELISA. When Recombinant Human FGF R4 Fc Chimera (Catalog # 685-FR ) is immobilized at 5 µg/mL (100 µL/well), the concentration range of Recombinant Human FGF-19 that produces 50% of the optimal binding response is 20-120 ng/mL.

endotoxin note :

<0.10 EU per 1 µg of the protein by the LAL method.

catalog number base :

969-FG

accessionNumbers :

O95750

applications :

Binding Activity

source :

E. coli -derived human FGF-19 protein Leu25-Lys216

2020 USD :

259

2021 USD :

259 USD

alt names :

FGF19, FGF-19, fibroblast growth factor 19

storage :

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.